XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.2
REVENUE
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenues for the three and six months ended June 30, 2025 and 2024 (in thousands): 
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Product sales, net:
ROLVEDON$16,128 $15,144 $29,249 $29,622 
INDOCIN products3,033 6,913 8,578 15,596 
Sympazan3,244 2,668 5,423 5,285 
SPRIX1,976 2,147 3,565 3,584 
Other products4,441 3,823 8,003 8,470 
Total product sales, net28,822 30,695 54,818 62,557 
Royalty revenue400 431 894 1,017 
Total revenues$29,222 $31,126 $55,712 $63,574 
Product Sales, net

Product sales, net, consist of sales of the Company’s products as listed above. Other product sales, net, for the three and six months ended June 30, 2025 and June 30, 2024 represent product sales for Otrexup, CAMBIA and Zipsor. During the first quarter of 2025, the Company reclassified product sales from Otrexup and CAMBIA to the Other products line in the table above. Prior period amounts were reclassified herein to conform with the current period presentation. As discussed in Note 2. Divestitures and Strategic Transactions, the Company ceased commercialization of Otrexup beginning in July 2025.

The Company reviews its estimates related to its accrued rebates, returns and discounts, including those recorded in prior periods, on a frequent basis and makes adjustments to those allowances as needed. Those adjustments to revenue recognized for products sold in prior periods were approximately 21% and 11% of Total product sales, net, for the three and six months ended June 30, 2025, respectively, and less than 1% for both the three and six months ended June 30, 2024. The adjustment for each of the three and six months ended June 30, 2025 included the adjustment of a prior period returns reserve of $5.4 million established in connection with the Company’s acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) in July 2023 (“the Spectrum Merger”).
Royalty Revenue

In November 2010, the Company entered into a license agreement granting Tribune Pharmaceuticals Canada Ltd. (later known as Aralez Pharmaceuticals, Miravo Healthcare, and now Searchlight Pharma, or “Searchlight,” owned by Apotex Inc.) the rights to commercially market CAMBIA in Canada. Searchlight independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalty revenue related to the CAMBIA licensing agreement of $0.4 million and $0.9 million for the three and six months ended June 30, 2025, respectively, and $0.4 million and $1.0 million for the three and six months ended June 30, 2024, respectively.